Prostate MRI
Clarity before the biopsy. Assessed by the PI-RADS standard.
An elevated PSA value alone says little about the cause – a benign enlargement or an inflammation can raise it too. Multiparametric MRI images the prostate without X-rays and makes suspicious areas visible in a targeted way – the basis for a targeted rather than a blind biopsy.
- Fast appointmentsWeekends too – by arrangement
- Personal discussion of your resultsThorough and clear about next steps, directly after the examination
- Onward care in MunichIf findings are serious, we promptly refer you to specialist colleagues and hospitals
- Radiology & CardiologyUnder one roof – short distances
Two good reasons to look closer
With an elevated or rising PSA value
Before a biopsy is due, MRI clarifies whether and where a suspicious area exists at all – an established part of the work-up according to the current S3 guideline.¹
Blood in the urine or semen
Early prostate cancer rarely causes symptoms. Signs such as blood in the urine (haematuria) or in the semen (haematospermia) usually have harmless causes, but should be evaluated by a urologist.
Unusual pain or problems passing urine
New complaints when passing urine or unusual pain in the pelvis are likewise usually harmless, but should be investigated. If a biopsy is then being considered, mpMRI helps to proceed in a targeted rather than blind manner.⁵
For follow-up and active surveillance
With a known low-risk finding, MRI allows radiation-free observation over time – often the basis for postponing or avoiding an intervention.
One examination made of several sequences
Multiparametric MRI (mpMRI) is one examination that combines several imaging techniques into a single picture and is assessed in a structured way according to the international PI-RADS standard. The following sequences are its building blocks – not separately selectable procedures.
T2-weighted sequences
High-resolution anatomical images show the zones of the prostate in fine detail – the basis for assessing the gland cleanly, layer by layer.
Diffusion imaging (DWI)
Makes differences in tissue density visible – a particularly sensitive parameter for assessing conspicuous areas, complemented by the ADC map.
Contrast sequence (DCE)
The dynamic acquisition shows the perfusion behaviour of the tissue – a complementary building block of the multiparametric assessment.
PI-RADS reporting
All sequences come together in a structured assessment according to PI-RADS 2.1² – with clear classification of each lesion and a comprehensible recommendation.
A finding is not a verdict. It is the beginning of a conversation.
Three steps to certainty
Book an appointment
Conveniently online or by phone – you receive an appointment promptly through our friendly reception.
The examination
The scan is performed in a modern wide-bore MRI with a short magnet – comfortable even with claustrophobia. The contrast agent is given via an arm vein.
Findings & discussion
You receive a detailed PI-RADS report and a personal discussion of the next steps – in coordination with your urologist.
Personally there for you
Dr. Dr. Georg-Friedemann Rust
Physicist and radiologist – combining medical and technical expertise for precise imaging and personal care.
Trust that grows from experience
★★★★★ 87 × 5-star reviews on Google
Gain clarity
Arrange your appointment – online in a few steps or by phone.
Prostate cancer is the most common cancer in men in Germany – in 2023 alone around 79,600 new cases were registered, and around 15,000 men die from it each year.³ An elevated PSA value alone, however, says little about the cause: a benign enlargement or an inflammation can raise it too. Multiparametric MRI is an established part of primary diagnostics according to the current S3 guideline¹ and combines T2, diffusion and contrast sequences into a structured assessment according to PI-RADS 2.1.² This makes suspicious areas visible in a targeted way – the basis for a targeted rather than a blind biopsy and, in many cases, for a well-founded decision against an unnecessary intervention.⁴ Whether mpMRI makes sense in your case is something we clarify together and in coordination with your urologist.
- Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 8.1, August 2025. AWMF-Registernummer 043-022OL. register.awmf.org
- Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76(3):340–351. doi:10.1016/j.eururo.2019.02.033 europeanurology.com
- Robert Koch-Institut, Zentrum für Krebsregisterdaten (ZfKD), und Deutsche Krebsregister e. V. (Hrsg.). Krebs in Deutschland für 2021–2023. 15. Ausgabe, 2025. doi:10.25646/13129 krebsdaten.de
- Kasivisvanathan V, Rannikko AS, Borghi M, et al.; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018;378(19):1767–1777. doi:10.1056/NEJMoa1801993 nejm.org
- Ahmed HU, El-Shater Bosaily A, Brown LC, et al.; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389(10071):815–822. doi:10.1016/S0140-6736(16)32401-1 thelancet.com